UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 340

Sortiert nach

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

Proceedings of the National Academy of Sciences - PNAS, 2016-03, Vol.113 (11), p.E1419-E1420

2016

Volltextzugriff (PDF)

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins

Clinical cancer research, 2018-12, Vol.24 (23), p.5807-5814

2018

Volltextzugriff (PDF)

Autophagy as a target for anticancer therapy

Nature reviews. Clinical oncology, 2011-09, Vol.8 (9), p.528-539

2011

Volltextzugriff (PDF)

Phase I trials as valid therapeutic options for patients with cancer

Nature reviews. Clinical oncology, 2019-12, Vol.16 (12), p.773-778

2019

Volltextzugriff (PDF)

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

The New England journal of medicine, 2023-01, Vol.388 (1), p.33-43

2023

Volltextzugriff (PDF)

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Nature (London), 2019-11, Vol.575 (7781), p.217-223

2019

Volltextzugriff (PDF)

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Clinical cancer research, 2017-03, Vol.23 (6), p.1388-1396

2017

Volltextzugriff (PDF)

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

Clinical cancer research, 2009-11, Vol.15 (22), p.7061-7068

2009

Volltextzugriff (PDF)

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Clinical cancer research, 2020-09, Vol.26 (17), p.4531-4541

2020

Volltextzugriff (PDF)

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

European journal of endocrinology, 2022-06, Vol.186 (6), p.631

2022

Volltextzugriff (PDF)

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Clinical cancer research, 2021-10, Vol.27 (19), p.5236-5247

2021

Volltextzugriff (PDF)

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Nature medicine, 2023-01, Vol.29 (1), p.115-126

2023

Volltextzugriff (PDF)

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Clinical cancer research, 2020-03, Vol.26 (6), p.1237-1246

2020

Volltextzugriff (PDF)

Dyslexia in Pediatrics: Simple Practices to Tackle a Complex Issue

Pediatrics (Evanston), 2020-07, Vol.146 (1), p.e20201470

2020

Volltextzugriff (PDF)

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

Cancer research (Chicago, Ill.), 2013-01, Vol.73 (1), p.276-284

2013

Volltextzugriff (PDF)

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

Clinical cancer research, 2014-09, Vol.20 (18), p.4827-4836

2014

Volltextzugriff (PDF)

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

Clinical cancer research, 2012-05, Vol.18 (9), p.2625-2631

2012

Volltextzugriff (PDF)

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

Clinical cancer research, 2021-11, Vol.27 (21), p.5781-5792

2021

Volltextzugriff (PDF)

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Clinical cancer research, 2018-01, Vol.24 (1), p.181-188

2018

Volltextzugriff (PDF)

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway

Clinical cancer research, 2018-03, Vol.24 (5), p.1138-1151

2018

Volltextzugriff (PDF)

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Nature medicine, 2023-01, Vol.29 (1), p.104-114

2023

Volltextzugriff (PDF)

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

Clinical cancer research, 2018-07, Vol.24 (14), p.3263-3272

2018

Volltextzugriff (PDF)

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

Clinical cancer research, 2020-04, Vol.26 (8), p.1924-1931

2020

Volltextzugriff (PDF)

1 – 25 von 340

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

Zeitschrift / SeriePlos One

SpracheJapanisch

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(330)
Mit Volltextzugriff
(269)

Publikationsform

Sprache

Englisch
(337)
Koreanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins

Autophagy as a target for anticancer therapy

Phase I trials as valid therapeutic options for patients with cancer

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study

Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Dyslexia in Pediatrics: Simple Practices to Tackle a Complex Issue

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses

Intratumoral Injection of Clostridium novyi -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma

Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway

Autologous T cell therapy for MAGE-A4 + solid cancers in HLA-A02 + patients: a phase 1 trial

Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer

Aktive Filter

Suchergebnisse filtern